Journal of Clinical Oncology

CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.

Journal of Clinical Oncology

Gregory P. Botta, Ronan Joseph Kelly, Zhaohui Jin, Hong Ma, Geoffrey Yuyat Ku, Dan Zhao, Rutika Mehta, Julia C. Carnevale, Gloria Sierra, Jie JIA, Raffaele Baffa, Zhonghai Li, Dae Won Kim, Harry H. Yoon

The cognitive load of inpatient consults involving immune-related adverse events.

Journal of Clinical Oncology

Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Journal of Clinical Oncology

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).

Journal of Clinical Oncology

Catherine Choy Smith, Pankit Vachhani, Guillermo Garcia-Manero, Nicole Renee Grieselhuber, Guru Subramanian Guru Murthy, Astha Bhatia, Jatinder Arora, Hooman Izadi, Anthony Fiorino, Raajit Rampal

Should I stay, or should I go? Factors associated with intent to leave academic oncology.

Journal of Clinical Oncology

Ana I. Velazquez Manana, Bismarck Odei, Narjust Florez, Sankalp Pandya, Valerie M Dandar, Dame Idossa, Bridget P. Keenan, Katherine Van Loon, Fumiko Chino

Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.

Journal of Clinical Oncology

Maira Soto, Erin L Filbert, Hai Yang, Li Zhang, Stephanie Starzinski, Alec Starzinski, Alexander Cheung, Tony Li, Frank J. Hsu, Andrew H. Ko, Lawrence Fong, Bridget P Keenan

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Journal of Clinical Oncology

Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng

A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).

Journal of Clinical Oncology

Hewitt Chang, Luchia Andemicael, Moshiur Mekhail Anwar, John Gordan, Jamese Johnson, Bridget P Keenan, Robin Kate Kelley, Andrew H. Ko, Katherine Van Loon, Alan P. Venook, Lawrence Fong, Melody Ju Xu, Mary Uan-Sian Feng

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology

Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman

Pages